Half of US adults have received one COVID-19 vaccine dose

Half of U.S. adults have received at least one dose of a Covid-19 vaccine, the Centers for Disease Control and Prevention disclosed. About one-third of adults are also fully vaccinated.

The latest figures reveal just how robust the U.S. national Covid-19 vaccination program is, with three FDA-approved vaccines. Roughly 211 million vaccine doses have been administered in the U.S. as of April 19, according to the CDC. However, the CDC recently recommended a pause of the Johnson & Johnson Covid-19 vaccine after six women experienced a rare blood clot associated with the vaccine.

The latest figures from the CDC comes as the number of Covid-19 cases and deaths continue to rise across the nation. At the time of publication, there were nearly 31.5 million Covid-19 cases and 564,292 reported deaths.

Among seniors, who have been hardest hit by the disease, 80.1% have received one vaccine dose, and nearly 65% were fully vaccinated. 

Despite the pause on the Johnson & Johnson vaccine, which is administered in one dose, U.S. public health officials remain bullish on the vaccination rollout. The current pace of vaccinations tops 3 million per day, putting President Biden on track to meet his goal of 200 million doses within his first 100 days in office, according to a statement from Jeff Zients, White House Covid-19 response coordinator.

“Based on actions taken by the President earlier this year, the United States has secured enough Pfizer and Moderna doses for 300 million Americans,” Zients said.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.